Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in obese patients with heart failure with preserved ejection fraction (HFpEF)
ChiCTR2500113927Phase 2Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and obesity comparing HRS9531 injection with Placebo injection (2 arms). Primary endpoints: Change in KCCQ-CSS at week 36 and Percentage change in body weight at week 36. Started Dec 2025; status: recruiting.
02
Drugs
HRS9531
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on ChiCTR2500113927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113927.